Health Care·Biotechnology·$28.9B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.25 | N/A | +11.97% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-1.25 | N/A | +11.97% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Overall, management expressed caution regarding future performance. They acknowledged the difficulties faced in the current economic climate.
Management highlighted ongoing challenges in the current market environment.
They emphasized the need for strategic adjustments moving forward.
Natera's earnings report indicates a challenging quarter, particularly with the EPS figure showing a loss. The stock's slight decline of 0.59% reflects investor concerns about the company's future performance and the lack of revenue data. Management's defensive tone suggests they are aware of the hurdles ahead and are preparing for potential adjustments.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
TAKE-TWO INTERACTIVE
Nov 7, 2022